FUNDAMENTALS · Fundamentals · TW Healthcare

Visco Vision (6782) Fundamentals 2026 — P/E 12.7x, Revenue Analysis | SniperIQ

Visco Vision (6782) is a TW-listed Healthcare company in Medical - Instruments & Supplies with a market capitalization of NT

1.9B, trading at NT
88.50 on the TAI. This SniperIQ fundamentals page covers Visco Vision's valuation (P/E 12.7x, P/B 2.8x), profitability (net margin 20.7%), revenue (NT$4.2B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Market CapNT
1.9B
P/E (TTM)12.7x
Net Margin20.7%
Revenue (FY25)NT$4.2B

Full research coverage

  • 8-Quarter Revenue & Margin Trend
  • Debt Maturity & Coverage
  • Peer Valuation Comparison
  • Free Cash Flow & Owner Earnings
  • AI Signal + Institutional Flow
  • DCF Valuation Model

Frequently Asked Questions

What is Visco Vision's market cap?

Visco Vision (6782) has a market capitalization of approximately NT

1.9B, trading at NT
88.50 on the TAI. Market cap moves with the live share price.

What is Visco Vision's P/E ratio?

Visco Vision's trailing twelve-month P/E ratio is 12.7x, with a price-to-book (P/B) of 2.8x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is Visco Vision?

Visco Vision runs a net profit margin of 20.7%, a gross margin of 45.8%, and an operating margin of 28.8%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does Visco Vision generate?

Visco Vision reported revenue of NT$4.2B for fiscal year 2025, with net income of NT$887M and earnings per share (EPS) of 14.08. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does Visco Vision pay a dividend?

Visco Vision offers a trailing dividend yield of about 4.5%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.

Is Visco Vision financially healthy?

Visco Vision carries a debt-to-equity ratio of 0.11x and a current ratio of 1.26x, with a market beta of 0.56. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is Visco Vision a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Visco Vision (6782) the key facts are: market cap NT

1.9B, P/E 12.7x, revenue NT$4.2B, 52-week range 165.5-241. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.

Track Visco Vision's full fundamentals live

Get Visco Vision's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.

Related: Gongwin Biopharm Holdings (6617) fundamentals · Nahdi Medical (4164) fundamentals · Staidson (Beijing) BioPharmaceuticals (300204) fundamentals · Tibet Cheezheng Tibetan Medicine (002287) fundamentals · All stock fundamentals · AI signal library
Research Hubs: Fundamentals library · Screeners · Institutional positioning · Super investors · Daily signals · Platform comparisons